结外NK/T细胞淋巴瘤患者24个月无进展生存期与后续生存:中国淋巴瘤协作组研究
该研究基于中国淋巴瘤协作组数据库1790例结外NK/T细胞淋巴瘤患者,分析24个月无进展生存(PFS24)后的后续总生存(OS)。未达PFS24者进展后中位OS仅5.3个月,5年OS率19.2%,标化死亡比71.4;达PFS24者占74%,后续标化死亡比1.77,5年OS率92.2%接近一般人群预期94.3%。
要点
- 未达PFS24者进展后生存极差,5年OS率仅19.2%。
- 达PFS24者占74%,5年OS率92.2%接近一般人群预期。
- PFS24或可用于ENKTCL研究设计与风险分层。
核心结论
- 达到PFS24的患者预后极好,而早期进展者生存极差,PFS24或可用于ENKTCL研究设计与风险分层。
研究设计与样本
- 基于中国淋巴瘤协作组(CLCG)数据库的多中心队列研究,纳入1790例结外NK/T细胞淋巴瘤患者。
- 后续OS定义为从PFS24或24个月内进展至死亡的时间,并与年龄性别匹配的一般中国人群比较标化死亡比(SMR)。
主要发现
- 未达PFS24者进展后中位OS为5.3个月,5年OS率19.2%,SMR为71.4(95%CI 62.9-81.1)。
- 74%患者达到PFS24,达标后SMR为1.77(95%CI 1.34-2.34)。
- PFS24后5年观察OS率为92.2%,预期OS率为94.3%。
- 早期患者达到PFS24后5年OS率为92.9%。
临床怎么用
- 可将PFS24作为ENKTCL疗效评估和风险分层的早期终点,达PFS24者后续生存接近一般人群。
- 未达PFS24者进展后生存极差,需积极考虑后续治疗或临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of patients. 1790 patients were included from the China Lymphoma Collaborative Group (CLCG) database. Subsequent OS was defined from the time of PFS24 or progression within 24 months to death. OS was compared with age- and sex-matched general Chinese population using expected survival and standardized mortality ratio (SMR). Patients who did not achieve PFS24 had a median OS of 5.3 months after progression, with 5-year OS rate of 19.2% and the SMR of 71.4 (95% CI, 62.9-81.1). In contrast, 74% patients achieved PFS24, and the SMR after achieving PFS24 was 1.77 (95% CI, 1.34-2.34). The observed OS rate after PFS24 versus expected OS rate at 5 years was 92.2% versus 94.3%. Similarly, superior outcomes following PFS24 were observed in early-stage patients (5-year OS rate, 92.9%). Patients achieving PFS24 had excellent outcome, whereas patients exhibiting earlier progression had a poor survival. These marked differences suggest that PFS24 may be used for study design and risk stratification in ENKTCL.
引用
- Yang Y, Wang Y, Liu X, et al. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia. 2020. PMID: 32943751. doi:10.1038/s41375-020-01042-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。